Coping in caregivers of patients with primary malignant brain tumors: A mediation analysis of a randomized controlled trial.
Deborah Anne Forst,Kelcie D Willis,Sumita Madhok Strander,Jessica Devon Whitman,Daniel Chiu,Nora K. Horick,Kedie Pintro,Areej El-Jawahri,Joseph A. Greer,Jennifer S. Temel,Jamie M. Jacobs
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.12110
IF: 45.3
2024-06-01
Journal of Clinical Oncology
Abstract:12110 Background: Caregivers of patients with primary malignant brain tumors (PMBT) experience immense psychological distress and lack tailored supportive care resources. In a recently completed randomized controlled trial, we demonstrated that a brief telehealth-based psychological intervention (“NeuroCARE”) for caregivers of patients with PMBT led to decreased anxiety and depression symptoms as well as greater caregiving self-efficacy and coping ability compared to usual care (UC). To explore active drivers of the intervention, we examined whether improvements in caregivers’ coping ability mediated the effects of NeuroCARE on psychosocial outcomes. Methods: From October 2019 to June 2022, we enrolled 120 adult caregivers (mean age 53 years, 83% female, 70% spouse/partner) of patients newly diagnosed with a PMBT to a trial of NeuroCARE vs. UC. Eligible caregivers had elevated baseline anxiety (Generalized Anxiety Disorder-7 ≥ 5). Caregivers self-reported their anxiety symptoms (Hospital Anxiety and Depression Scale-Anxiety), depression symptoms (Hospital Anxiety and Depression Scale-Depression), coping skills (Measure of Current Status), and caregiving self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline and 11 weeks (post-intervention). We ran three causal mediation regression models with bias-corrected bootstrapping to examine whether intervention effects on anxiety symptoms, depression symptoms, and self-efficacy at 11 weeks were mediated by changes in coping ability from baseline to 11-weeks. Results: Improvements in anxiety symptoms at 11 weeks in caregivers assigned to NeuroCARE, compared to those receiving UC, were mediated by increased coping ability across the 11 weeks. Improved coping ability led to a 1.44 decrease in anxiety on the HADS-A for patients assigned to NeuroCARE (indirect effect = -1.44, bootstrapped SE = 0.49, 95% CI [-2.50, -0.54]). This indirect effect accounted for 75% of the total intervention effect on anxiety. Similarly, NeuroCARE-related reductions in 11-week depression symptoms were mediated by improved coping ability (indirect effect = -1.43, bootstrapped SE = 0.38, 95% CI [-2.21, -0.74], 82% of the total effect), as were increases in caregiving self-efficacy (indirect effect = 11.03, bootstrapped SE = 2.59, 95% CI [6.30, 16.53], 63% of the total effect). Conclusions: The beneficial effects of the intervention on caregivers’ anxiety symptoms, depression symptoms, and self-efficacy were driven indirectly by caregivers’ use of evidence-based coping skills learned in NeuroCARE. The identification of coping as an active intervention component is critical for optimizing the scalability and sustainability of NeuroCARE for this highly burdened and distressed PMBT caregiver population. Clinical trial information: NCT04109209 .
oncology